The Estimated Direct Medical Cost of Selected Sexually Transmitted Infections in the United States, 2008
The Estimated Direct Medical Cost of Selected Sexually Transmitted Infections in the United States, 2008
复制标题
DOI：
10.1097/olq.0b013e318285c6d2
复制
发表时间：
2013-03-01
影响因子：
3.1
通讯作者：
Kent, Charlotte K.
中科院分区：
文献类型：
--
作者：
Owusu-Edusei, Kwame, Jr.;Chesson, Harrell W.;Kent, Charlotte K.
背景：美国每年发生数以百万计的性传播感染(STI)病例，给国家带来了巨大的医疗成本。以前对性传播感染总直接成本的估计相当陈旧。我们提供了美国最新的性传播感染直接医疗成本估算。方法：我们收集了最近(即2002-2011年)的成本估算，以确定8种主要性传播感染(衣原体、淋病、乙肝病毒、人类免疫缺陷病毒(HIV)、人乳头瘤病毒、生殖器单纯疱疹病毒2型、滴虫病和梅毒)的每个病例的终身成本。每一次性传播感染的总直接成本是2008年新病例或新诊断病例数与每个病例的估计折现终生成本的乘积。结果：结果表明，2008年美国所有年龄段人群中发生的1970万例性传播感染患者的一生直接医疗总成本为156亿美元(范围为11.0-206亿美元)。总费用如下：衣原体(516.7美元[258.3-775.0美元])，淋病(162.1美元[8,110万-243.2美元])，乙肝病毒(5,070万美元[4,130-5,560万美元])，艾滋病毒(1，26亿美元[9,570亿美元])，人类乳头瘤病毒(1，7亿美元[8-2 9亿美元])，单纯疱疹病毒2型(540.7美元[270.3-811.0美元])，梅毒(3,930-5,890万美元)，滴虫病(2400万美元[1200万-3600万美元])。与艾滋病毒感染相关的费用占总费用的81%以上。在非病毒性性病中，衣原体感染是最昂贵的感染。结论：性传播感染继续给美国的医疗保健支付者带来巨大的成本负担。如果没有预防和控制性传播感染的努力，性传播感染的负担将更加沉重。
Background: Millions of cases of sexually transmitted infections (STIs) occur in the United States each year, resulting in substantial medical costs to the nation. Previous estimates of the total direct cost of STIs are quite dated. We present updated direct medical cost estimates of STIs in the United States.Methods: We assembled recent (i.e., 2002-2011) cost estimates to determine the lifetime cost per case of 8 major STIs (chlamydia, gonorrhea, hepatitis B virus, human immunodeficiency virus (HIV), human papillomavirus, genital herpes simplex virus type 2, trichomoniasis and syphilis). The total direct cost for each STI was computed as the product of the number of new or newly diagnosed cases in 2008 and the estimated discounted lifetime cost per case. All costs were adjusted to 2010 US dollars.Results: Results indicated that the total lifetime direct medical cost of the 19.7 million cases of STIs that occurred among persons of all ages in 2008 in the United States was $15.6 (range, $11.0-$20.6) billion. Total costs were as follows: chlamydia ($516.7 [$258.3-$775.0] million), gonorrhea ($162.1 [$81.1-$243.2] million), hepatitis B virus ($50.7 [$41.3-$55.6] million), HIV ($12.6 [$9.5-$15.7] billion), human papillomavirus ($1.7 [$0.8-$2.9] billion), herpes simplex virus type 2 ($540.7 [$270.3-$811.0] million), syphilis ($39.3 [$19.6-$58.9] million), and trichomoniasis ($24.0 [$12.0-$36.0] million). Costs associated with HIV infection accounted for more than 81% of the total cost. Among the nonviral STIs, chlamydia was the most costly infection.Conclusions: Sexually transmitted infections continue to impose a substantial cost burden on the payers of medical care in the United States. The burden of STIs would be even greater in the absence of STI prevention and control efforts.